Short-term Prednisone therapy reduces disease severity in newly diagnosed RA patients: Study
Temporary use of low dose prednisone monotherapy leads to disease remission and improved clinical severity of the majority of newly diagnosed patients with rheumatoid arthritis (RA), suggests a study published in the Adv Rheumatol
The ACR/EULAR recommendations endorse the use of glucocorticoids (GCs) for rheumatoid arthritis (RA) patients' flares and as a bridge to a DMARD. However, the recommendation of low dose short-term monotherapy with glucocorticoids (GCs) remains open to the discretion of the clinician.
A group of researchers from U.S.A conducted a study to assess whether short-term use of low dose prednisone monotherapy was effective in inducing remission in newly diagnosed for rheumatoid arthritis (RA).
The researchers performed a retrospective analysis of patients newly diagnosed with rheumatoid arthritis (RA) at a Community Health Center in North Dakota was performed based on the ACR/EULAR RA classification criteria. Demographic and clinical data were abstracted from patients' medical charts. Patients treated with (< 10 mg/day) of prednisone up to 6 months were included. Response to prednisone was analyzed according to pre- and post-treatment DAS28-ESR score and EULAR response criteria.
The results of the study are as follows:
- Data on 201 patients were analyzed.
- The mean prednisone dose was 8 mg/day and the mean treatment duration was 42.2 days Disease severity significantly improved from baseline to follow-up for the tender joint count, swollen joint count, and visual analog pain score.
- DAS28-ESR disease severity significantly improved from baseline to follow-up.
- Per EULAR response criteria, 69.7% of patients showed good response to treatment and 20.4% showed a moderate response. 54.2% of patients reached remission.
Thus, the researchers concluded that short-term use of low dose prednisone monotherapy induced disease remission and improved clinical severity of rheumatoid arthritis in the majority of newly diagnosed patients.
Reference:
The efficacy of low dose short-term prednisone therapy for remission induction in newly diagnosed rheumatoid arthritis patients by Stacy J et. al published in the Adv Rheumatol.
DOI: 10.1186/s42358-021-00205-4
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.